Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Mediastinal Large B Cell Lymphoma: early-phase trial registry
8 of 12 indexed Primary Mediastinal Large B Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 8 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Primary Mediastinal Large B Cell Lymphoma: 12 US clinical trials tracked, 8 recruiting.
Primary Mediastinal Large B Cell Lymphoma is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is University of Washington, running 2 of these trials.
Enrollment posture brief
Registry condition primary-mediastinal-large-b-cell-lymphoma
OPEN 8 | RECR 67% | LATE 1 | EARLY 10 | RANK #1429 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Primary Mediastinal Large B Cell Lymphoma lists 8 open slots (67% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Mediastinal Large B Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Mediastinal Large B Cell Lymphoma is recruiting above its size-band peers.
8 of 12 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Primary Mediastinal Large B Cell Lymphoma research.
University of Washington accounts for 2 of 12 trials (16.7%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Primary Mediastinal Large B Cell Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 36 among the 12 trials that report a genuine target (sentinel values excluded). 10 of those (83.3%) plan for fewer than 100 participants.
-
Primary Mediastinal Large B Cell Lymphoma research is mostly interventional.
11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
Academic and Community Cancer Research United
NCT06238648
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
University of Washington
NCT04231877
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
OHSU Knight Cancer Institute
NCT06784167
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Acepodia Biotech
NCT05653271
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
C. Babis Andreadis
NCT04545762
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
Jennifer Crombie, MD
NCT05934448
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Marcela V. Maus, M.D.,Ph.D.
NCT06550141
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
University of Washington
NCT07097363
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
National Cancer Institute (NCI)
NCT04759586
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
Memorial Sloan Kettering Cancer Center
NCT04464200
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Calibr, a division of Scripps Research
NCT04450069
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TCR2 Therapeutics
NCT04323657
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Mediastinal Large B Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Mediastinal Large B Cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Mediastinal Large B Cell Lymphoma page
12 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Primary Mediastinal Large B Cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Washington sponsors the most Primary Mediastinal Large B Cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See University of Washington's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Mediastinal Large B Cell Lymphoma condition card totals 12 registered trials; most-linked intervention Cyclophosphamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.